These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26576554)

  • 1. Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.
    Carr BI; Guerra V
    Dig Dis Sci; 2016 Mar; 61(3):937-47. PubMed ID: 26576554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
    Chon YE; Choi GH; Lee MH; Kim SU; Kim DY; Ahn SH; Kim KS; Choi JS; Han KH; Chon CY; Park JY
    Int J Cancer; 2012 Nov; 131(10):2332-41. PubMed ID: 22362471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype.
    Carr BI; Guerra V; Giannini EG; Farinati F; Ciccarese F; Ludovico Rapaccini G; Di Marco M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F;
    Semin Oncol; 2014 Apr; 41(2):252-8. PubMed ID: 24787296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low alpha-fetoprotein HCC and the role of GGTP.
    Carr BI; Guerra V; Giannini EG; Farinati F; Ciccarese F; Rapaccini GL; Di Marco M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F
    Int J Biol Markers; 2014 Dec; 29(4):e395-402. PubMed ID: 24832180
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R
    J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macroscopic Portal Vein Thrombosis in HCC Patients.
    Akkiz H; Carr BI; Kuran S; Karaoğullarından Ü; Üsküdar O; Tokmak S; Arslan B; Doran F; Balli HT; Ülkü A; Akçam TA; Bahçeci Hİ; Polat KY; Örmeci N; Şimşek H; Sonsuz A; Demir A; Altıntaş E; Demir M; Yalçın K; Ekinci N; Harmancı Özakyol A; Yücesoy M; Uygun A; Guerra V; Delik A; Tokat Y; Yilmaz S; Bektaş A; Kılıç M
    Can J Gastroenterol Hepatol; 2018; 2018():3120185. PubMed ID: 30009156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
    Dohmen K; Shigematsu H; Irie K; Ishibashi H
    Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of alpha-fetoprotein and des-gamma-carboxyprothrombin in nigerians with hepatocellular carcinoma.
    Ette AI; Ndububa DA; Adekanle O; Ekrikpo U
    Niger J Clin Pract; 2017 Oct; 20(10):1267-1272. PubMed ID: 29192630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
    Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
    Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
    Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
    World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma.
    Inoue S; Nakao A; Harada A; Nonami T; Takagi H
    Am J Gastroenterol; 1994 Dec; 89(12):2222-6. PubMed ID: 7526679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients.
    Akkiz H; Carr BI; Yalçın K K; Guerra V; Kuran S; Altıntaş E; Üsküdar O; Karaoğullarından Ü; Özakyol A; Tokmak S; Yücesoy M; Bahçeci Hİ; Ülkü A; Akçam T; Yalçın Polat K; Ekinci N; Şimşek H; Örmeci N; Sonsuz A; Demir M; Kılıç M; Uygun A; Ballı T; Demir A; Arslan B; Doran F
    Oncology; 2018; 94(2):116-124. PubMed ID: 29207378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
    Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
    Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Des-gamma-carboxyprothrombin for early identification and prognosis of hepatocellular carcinoma--a case control study from western Nepal.
    Mittal A; Gupta SP; Sathian B; Sreedharan J; Poudel B; Yadav SK; Pandeya DR
    Asian Pac J Cancer Prev; 2012; 13(11):5773-5. PubMed ID: 23317255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Yamamoto Y; Ikoma H; Morimura R; Shoda K; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
    World J Gastroenterol; 2015 Jan; 21(1):246-53. PubMed ID: 25574098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma.
    Okamura Y; Ashida R; Ito T; Sugiura T; Mori K; Uesaka K
    Surg Today; 2015 Dec; 45(12):1513-20. PubMed ID: 25527455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
    Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
    Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
    [No Abstract]   [Full Text] [Related]  

  • 18. Portal Vein Thrombosis and Markers of Inflammation in Hepatocellular Carcinoma.
    Carr BI; Guerra V; Donghia R
    J Gastrointest Cancer; 2020 Dec; 51(4):1141-1147. PubMed ID: 32851544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
    Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
    PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
    Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
    Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.